Steven Hildemann

Last updated on 2017-09-18T10:05+0300.

About this image

sign

Quotes... Extracted quotes from

Steven Hildemann said : "The CLARINET FORTE study is another example of Ipsen's commitment to delivering scientific and medical advances that translate into patient outcomes. Progressive pancreatic or midgut NETs are among the fastest growing class of cancers worldwide, so we are delighted that these data presented at ESMO may mean that for these patients, the need for aggressive second-line therapies could be delayed for longer whilst also benefitting from continued progression-free survival," External link

finanznachrichten-en Friday, September 18, 2020 8:43:00 AM EAT

Steven Hildemann said : “The CLARINET FORTE study is another example of Ipsen’s commitment to delivering scientific and medical advances that translate into patient outcomes. Progressive pancreatic or midgut NETs are among the fastest growing class of cancers worldwide, so we are delighted that these data presented at ESMO may mean that for these patients, the need for aggressive second-line therapies could be delayed for longer whilst also benefitting from continued progression-free survival,” External link

4-traders Friday, September 18, 2020 8:42:00 AM EAT

Steven Hildemann said : "The CLARINET FORTE study is another example of Ipsen's commitment to delivering scientific and medical advances that translate into patient outcomes. Progressive pancreatic or midgut NETs are among the fastest growing class of cancers worldwide, so we are delighted that these data presented at ESMO may mean that for these patients, the need for aggressive second-line therapies could be delayed for longer whilst also benefitting from continued progression-free survival," External link

afp-en Friday, September 18, 2020 8:00:00 AM EAT

Steven Hildemann said : "Merck is deeply committed to innovative science that improves the lives of patients living with severe diseases. Since its initiation, the funding of early stage research projects such as the Grant for Multiple Sclerosis Innovation, has enabled talented and inspiring researchers to advance our understanding of how we predict, diagnose, treat and monitor progression of this disabling disease," External link

prnewswire Thursday, October 26, 2017 11:11:00 PM EAT

Steven Hildemann said : "Merck is deeply committed to innovative science that improves the lives of patients living with severe diseases. Since its initiation, the funding of early stage research projects such as the Grant for Multiple Sclerosis Innovation, has enabled talented and inspiring researchers to advance our understanding of how we predict, diagnose, treat and monitor progression of this disabling disease," External link

itartass_en Thursday, October 26, 2017 10:32:00 PM EAT

Steven Hildemann said : "These findings reinforce and expand on the consistent and positive effect of Cladribine Tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability, and further our resolve to make this investigational therapy available for patients living with RRMS," External link

friedlnews Thursday, February 9, 2017 6:31:00 PM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck KGaA, Darmstadt, Germany's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

prnewswire Monday, October 10, 2016 10:06:00 AM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

prnewswire Monday, October 10, 2016 10:06:00 AM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck KGaA, Darmstadt, Germany's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

finanznachrichten-en Monday, October 10, 2016 9:51:00 AM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

finanznachrichten-en Monday, October 10, 2016 9:51:00 AM EAT

Steven Hildemann said : "Merck is committed to advancing care for patients living with multiple sclerosis through internal innovation and drug development, which is strategically complemented by external innovation from our Grant for Multiple Sclerosis Innovation," External link

itartass_en Friday, September 16, 2016 11:38:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
chief100.00%EN09/10/201710/09/2017
Names Lang Count
Steven HildemannEN85.71%
Steven HildemannDE14.29%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Tuesday, October 27, 2020

4:04:00 AM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

Steven Hildemann

Last updated on 2017-09-18T10:05+0300.

About this image

sign

Quotes... Extracted quotes from

Steven Hildemann said : "The CLARINET FORTE study is another example of Ipsen's commitment to delivering scientific and medical advances that translate into patient outcomes. Progressive pancreatic or midgut NETs are among the fastest growing class of cancers worldwide, so we are delighted that these data presented at ESMO may mean that for these patients, the need for aggressive second-line therapies could be delayed for longer whilst also benefitting from continued progression-free survival," External link

finanznachrichten-en Friday, September 18, 2020 8:43:00 AM EAT

Steven Hildemann said : “The CLARINET FORTE study is another example of Ipsen’s commitment to delivering scientific and medical advances that translate into patient outcomes. Progressive pancreatic or midgut NETs are among the fastest growing class of cancers worldwide, so we are delighted that these data presented at ESMO may mean that for these patients, the need for aggressive second-line therapies could be delayed for longer whilst also benefitting from continued progression-free survival,” External link

4-traders Friday, September 18, 2020 8:42:00 AM EAT

Steven Hildemann said : "The CLARINET FORTE study is another example of Ipsen's commitment to delivering scientific and medical advances that translate into patient outcomes. Progressive pancreatic or midgut NETs are among the fastest growing class of cancers worldwide, so we are delighted that these data presented at ESMO may mean that for these patients, the need for aggressive second-line therapies could be delayed for longer whilst also benefitting from continued progression-free survival," External link

afp-en Friday, September 18, 2020 8:00:00 AM EAT

Steven Hildemann said : "Merck is deeply committed to innovative science that improves the lives of patients living with severe diseases. Since its initiation, the funding of early stage research projects such as the Grant for Multiple Sclerosis Innovation, has enabled talented and inspiring researchers to advance our understanding of how we predict, diagnose, treat and monitor progression of this disabling disease," External link

prnewswire Thursday, October 26, 2017 11:11:00 PM EAT

Steven Hildemann said : "Merck is deeply committed to innovative science that improves the lives of patients living with severe diseases. Since its initiation, the funding of early stage research projects such as the Grant for Multiple Sclerosis Innovation, has enabled talented and inspiring researchers to advance our understanding of how we predict, diagnose, treat and monitor progression of this disabling disease," External link

itartass_en Thursday, October 26, 2017 10:32:00 PM EAT

Steven Hildemann said : "These findings reinforce and expand on the consistent and positive effect of Cladribine Tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability, and further our resolve to make this investigational therapy available for patients living with RRMS," External link

friedlnews Thursday, February 9, 2017 6:31:00 PM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck KGaA, Darmstadt, Germany's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

prnewswire Monday, October 10, 2016 10:06:00 AM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

prnewswire Monday, October 10, 2016 10:06:00 AM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck KGaA, Darmstadt, Germany's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

finanznachrichten-en Monday, October 10, 2016 9:51:00 AM EAT

Steven Hildemann said : "The Grant for Oncology Innovation is an example of Merck's commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future," External link

finanznachrichten-en Monday, October 10, 2016 9:51:00 AM EAT

Steven Hildemann said : "Merck is committed to advancing care for patients living with multiple sclerosis through internal innovation and drug development, which is strategically complemented by external innovation from our Grant for Multiple Sclerosis Innovation," External link

itartass_en Friday, September 16, 2016 11:38:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
chief100.00%EN09/10/201710/09/2017
Names Lang Count
Steven HildemannEN85.71%
Steven HildemannDE14.29%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Tuesday, October 27, 2020

4:04:00 AM EAT


Quotes... Explore Relations


EMM Visual Explorer